Abstract
Fourteen patients with purulent skin diseases were treated orally with fosfomycin (FOM) 1.5-3g in the tablet form for 1 week to determine its efficacy andsafety. The results obtained are summarized as follows.
1. The clinical efficacy rate was 71.4%. A bacteriological eradication rate of 71.4% was obtained.
2. As adverse reactions 3 patients experienced diarrhea and abdominal pain. But in all of these patients, symptoms were relieved with a reduction in dosage.
3. Taking the efficacy and the safety into account, utility rate was assessed to be 71.4%.
From these results it is considered that FOM tablets are useful equally to conventional FOM capsules.
